273 - Outcomes for Anti-CD19+ Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Non Hodgkin Lymphoma (NHL) across a Large Community Transplant and Cellular Therapy Network

Authors

Usama Gergis MD, MBA, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

2-2023

Volume

29

Issue

2

Published In/Presented At

10.1016/S2666-6367(23)00342-1

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine, Hematology-Medical Oncology Division, Lehigh Valley Topper Cancer Institute

Document Type

Article